STRUCTURE OF ONCOLYTIC VIRUS COMPRISING BISPECIFIC NUCLEIC ACID MOLECULE

The present invention relates to an anti-tumor adenovirus and an anticancer composition comprising same. Double-stranded siRNA of the present invention simultaneously inhibits the expression of a first nucleic acid and a second nucleic acid, thus promoting the death of cancer cells, exhibits more re...

Full description

Saved in:
Bibliographic Details
Main Authors PETER CHARLES, Goughnour, YOO, Jung-Ki, UM, Ki-Hwan, CHOI, Jin-Woo, LEE, Eui-Jin, CHOI, Chung-Gab, LEE, Hyung-Been, PARK, Seong-Hoon
Format Patent
LanguageEnglish
French
German
Published 25.01.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to an anti-tumor adenovirus and an anticancer composition comprising same. Double-stranded siRNA of the present invention simultaneously inhibits the expression of a first nucleic acid and a second nucleic acid, thus promoting the death of cancer cells, exhibits more remarkable anticancer activity as compared to co-treatment of respective siRNAs, has a synergistic effect of improving cancer cell death in combined treatment with an anticancer agent. The adenovirus comprising a shRNA-encoding expression cassette expressing the double-stranded siRNA, and a hTERT promoter evades immune responses in the body and is specifically delivered to cancer cells, thus having a systemic therapeutic effect, can be locally delivered, has excellent selectivity, and exhibits a significant anticancer effect even in minimally invasive treatment, and thus, the adenovirus can be effectively used as an anticancer composition or an anticancer adjuvant in various carcinomas.
Bibliography:Application Number: EP20210776088